Impact of Delayed Neoadjuvant Systemic Chemotherapy on Overall Survival Among Patients with Breast Cancer.
Debora de Melo GagliatoXiudong LeiSharon H GiordanoVicente ValeroCarlos H BarcenasGabriel N HortobagyiMariana Chavez-MacGregorPublished in: The oncologist (2020)
The results of this study showed that a delay in neoadjuvant systemic chemotherapy initiation of more than 61 days after breast cancer diagnosis is associated with an increased risk of death; therefore, efforts must focus on early initiation of therapy, which should be a priority. Multidisciplinary teams must enhance coordination of care and patient-centered, timely treatment planning and delivery.